ModifiedUnitedHealthcarePolicy CS195NE.I

Treatment of Temporomandibular Joint Disorders (for Nebraska Only)

Medical policy governing coverage and clinical rationale for non-surgical and surgical treatments for temporomandibular joint disorders for UnitedHealthcare members in Nebraska.

Policy Summary

PayerUnitedHealthcare

PolicyTreatment of Temporomandibular Joint Disorders (for Nebraska Only)

Policy CodePolicy CS195NE.I

Change TypeRevisions to unproven services list and updated reference links

Effective DateApr 1, 2025

Next Review Date

Key ActionVerify prior authorization and medical necessity against the applicable benefit plan and InterQual criteria before scheduling TMJ surgical procedures.

SourceLink

POLICY UPDATE CHANGES

Removed reference link to the Medical Benefit Drug Policy titled Sodium Hyaluronate.

Replaced 'passive rehabilitation therapy devices ... and low-load prolonged-duration stretch devices' with 'jaw mobility mechanical stretching devices (e.g., TheraBite, Jaw Dynasplint)'.

Revised list of examples of epigenetic appliances; added 'Advanced Lightwire Functional (ALF) appliances'.

Updated reference link to reflect the current policy title for Manipulation Under Anesthesia (for Nebraska Only).

Updated reference link to reflect the current policy title for Prolotherapy and Platelet Rich Plasma Therapies (for Nebraska Only).

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

1state-specific (Nebraska)

5proven non-surgical services

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

very low–moderateevidence quality range

48RCTs in occlusal splint meta-analysis

1policy versions archived

Coverage Criteria

inv-01: Non-surgical proven and medically necessary services

Covered when ALL of the following are met for non-surgical services

Non-surgical proven services: Arthrocentesis; Intra-articular corticosteroid injections; Trigger point injections; Physical therapy; Occlusal splints (stabilization and repositioning)

Listed as proven and medically necessary for treating TMJ disorders

inv-02: Surgical services (medically necessary in certain circumstances)

Surgical services stance and criteria reference

TMJ surgical services: Arthroscopy; Discectomy; Reconstruction; Arthroplasty (refer to InterQual CP and InterQual client-defined arthroplasty criteria for specific medical necessity coverage criteria)

Surgical services are medically necessary in certain circumstances; refer to InterQual CP for specific coverage criteria

inv-03: Unproven and not medically necessary services

Not medically necessary / unproven services

Unproven treatments: Craniosacral manipulation/therapy; Jaw mobility mechanical stretching devices (e.g., TheraBite Jaw Motion Rehabilitation System, Jaw Dynasplint System); Multiple occlusal splints (daytime and nighttime, maxillary and mandibular); Epigenetic appliances (e.g., Homeoblock, DNA Daytime/Nighttime appliance, Advanced Lightwire Functional (ALF) appliances)

Listed as unproven and not medically necessary due to insufficient evidence of efficacy

inv-04: Conservative and minimally invasive care pathway

Covered when ALL of the following are met

Conservative first‑line: Initial treatment should be conservative, reversible, and evidence‑based (for example: occlusal splint therapy, patient education/counseling, and physical therapy)

AADOCR recommends conservative reversible modalities initially; multimodal therapy (counseling + hard stabilization splint) may yield maximal improvement

Minimally invasive options for arthrogenous TMD: When arthrogenous subtype and goals warrant escalation, minimally invasive procedures (e.g., arthroscopy, arthrocentesis, intra‑articular injections such as corticosteroids or hyaluronic acid) may be considered as they can provide short‑ and intermediate‑term improvements in pain and maximum mouth opening compared with conservative therapy

Network meta-analyses show very low to moderate quality evidence favoring minimally invasive procedures for arthrogenous TMD; consider when conservative measures are inadequate and document treatment goals

Physical therapy addition: Addition of physical therapy (including TMJ, cervical and thoracic mobilization, soft tissue techniques and home exercises) to occlusal splint and education improves pain and maximum mouth opening in myogenic TMD

inv-05: Trigger‑point and needling therapies

Covered with criteria for trigger‑point/needling therapies

Needling therapies evidence summary: Needling therapies (dry needling, local anesthetic injections, platelet-rich plasma, botulinum toxin‑A) have shown short‑term improvements in pain and maximum mouth opening in randomized trials and network meta-analyses, but the overall quality of evidence is low to very low

Effectiveness did not clearly depend on needling type or substance; consider these therapies for myofascial TMD when conservative measures are insufficient, recognizing limited evidence and need for individualized documentation

inv-06: Unproven or insufficient evidence therapies

Not established / Unproven

Jaw mobility mechanical stretching devices (TheraBite, Jaw Dynasplint) are considered unproven due to limited, small or short‑term studies, low compliance, and inconclusive or unfavorable outcomes

Evidence is insufficient to establish efficacy or safety; these devices are considered experimental/unproven

Craniosacral manipulation and epigenetic appliances: Craniosacral manipulation/therapy and epigenetic appliances have no quality evidence demonstrating efficacy for TMD and are considered unproven/not medically necessary

Lack of quality evidence precludes concluding benefit on health outcomes

The following services are specifically listed as unproven and not medically necessary for temporomandibular joint (TMJ) disorders due to insufficient evidence of efficacy: craniosacral manipulation/therapy; jaw mobility mechanical stretching devices (for example, TheraBite Jaw Motion Rehabilitation System® and Jaw Dynasplint® System); multiple occlusal splints (e.g., daytime and nighttime splints, maxillary and mandibular combinations); and epigenetic appliances (for example, Homeoblock™, DNA® Daytime/Nighttime appliance, and Advanced Lightwire Functional [ALF] appliances).

Craniosacral manipulation/therapy and epigenetic intraoral appliances are excluded because a review of the medical literature did not identify quality evidence demonstrating their efficacy for TMD; consequently, the effect on health outcomes cannot be established. These therapies lack sufficient, high‑quality clinical trial data to support clinical benefit for TMJ disorders.

The policy’s revised list of unproven and not medically necessary services now explicitly includes jaw mobility mechanical stretching devices (e.g., TheraBite, Jaw Dynasplint) alongside previously listed therapies. This consolidated list reflects the policy determination that these devices and the named appliances do not have adequate evidence to support routine coverage for TMD.

Multiple occlusal splints used concurrently (for example, daytime plus nighttime or maxillary plus mandibular appliances) and the specified epigenetic appliances (Homeoblock™, DNA® daytime/nighttime devices, and ALF appliances) are identified in the policy as not medically necessary for treatment of TMJ disorders because available evidence does not demonstrate improved clinical outcomes for these approaches.

Jaw mobility mechanical stretching devices are considered not medically necessary / unproven because studies are limited by small sample sizes, short follow‑up, considerable loss to follow‑up, low compliance, and inconclusive or unfavorable results; therefore, a treatment effect on clinically meaningful outcomes for TMD cannot be established.

Specific jaw mobility mechanical stretching devices are listed among the services considered unproven, including the TheraBite Jaw Motion Rehabilitation System and the Jaw Dynasplint System; the policy revision replaced prior phrasing (e.g., 'passive rehabilitation' and 'low‑load prolonged‑duration stretch' devices) with the explicit term 'jaw mobility mechanical stretching devices' and named these examples.

Applicable Codes

Applicable procedure and DME codes (reference list, partial)mixed

20552	Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s).
20553	Injection(s); single or multiple trigger point(s), 3 or more muscles.
20605	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (e.g., temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa); without ultrasound guidance.
20606	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (e.g., temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa); with ultrasound guidance, with permanent recording and reporting.
21010	Arthrotomy, temporomandibular joint.
21050	Condylectomy, temporomandibular joint (separate procedure).
21060	Meniscectomy, partial or complete, temporomandibular joint (separate procedure).
21070	Coronoidectomy (separate procedure).
21085	Impression and custom preparation; oral surgical splint.
21089	Unlisted maxillofacial prosthetic procedure.

1–10 of 25

1/3

Prior authorization surgical CPT examplesCPT

29804	Arthroscopy, temporomandibular joint, surgical.
21243	Arthroplasty, temporomandibular joint, with prosthetic joint replacement.
21240	Arthroplasty, temporomandibular joint, with or without autograft (includes obtaining graft).
21010	Arthrotomy, temporomandibular joint.

Provider Actions and Operational Guidance

Prior Authorization

Prior Authorization / Clinical Criteria

Prior authorization and clinical review may be required for TMJ surgical procedures. UnitedHealthcare may reference InterQual® criteria (see Coverage Rationale) when reviewing requests. Providers should verify prior authorization requirements with the member's specific benefit plan before scheduling services.

InterQual® procedures referenced: Arthroscopy, Discectomy, Reconstruction, Arthroplasty
Confirm prior authorization requirements with the applicable federal, state, or contractual benefit plan terms

Note

Device Regulatory Status (Informational)

Device regulatory status is provided for informational purposes only. FDA approval or device class (e.g., Class III TMJ prostheses; Class II CPM machines) is not, by itself, a basis for coverage decisions.

FDA-regulated TMJ prostheses: Class III (PMA) — product codes LZD, MPI
Continuous passive motion (CPM) machines: Class II — product code BXB

Background

Temporomandibular disorders (TMD) are a group of conditions affecting the temporomandibular joint (TMJ) and/or the masticatory musculature, commonly producing jaw pain, limited mouth opening (reduced range of motion), and joint noises. Many TMD cases respond to conservative measures—such as education, soft diet, nonsteroidal anti‑inflammatory drugs, physical therapy, and occlusal splints—while refractory or severe cases may require targeted injections or surgical intervention after conservative care fails.

Definitions

inv-27: Arthrocentesis — key value definition of joint lavage/arthrocentesis

DefinitionMinimally invasive procedure to irrigate (lavage) the temporomandibular joint (TMJ) to reduce pain and improve mouth opening; may be performed with or without image guidance and can be combined with intra‑articular injectables.

PurposeUsed for treatment of arthrogenous TMJ disorders to relieve pain and improve maximum mouth opening (MMO).

Technique detailsIrrigation (single‑ or multi‑puncture arthrocentesis) with or without adjunct intra‑articular medications (e.g., corticosteroid, hyaluronic acid).

Evidence noteRandomized trials and systematic reviews compare arthrocentesis versus conservative therapy and arthroscopy for symptomatic internal derangement; arthrocentesis is among minimally invasive options evaluated for pain and MMO improvement.

inv-28: Occlusal splint — key value definition of stabilization or mandibular repositioning device

Revision History

2026-02-01related_policies_updatedLatest

Removed reference link to the Medical Benefit Drug Policy titled Sodium Hyaluronate.

2025-11-01related_policies_updated

Updated reference link to reflect the current policy title for Manipulation Under Anesthesia (for Nebraska Only).

2025-10-01related_policies_updated

Updated reference link to reflect the current policy title for Prolotherapy and Platelet Rich Plasma Therapies (for Nebraska Only).

Policy Summary

PayerUnitedHealthcare

PolicyTreatment of Temporomandibular Joint Disorders (for Nebraska Only)

Policy CodePolicy CS195NE.I

Change TypeRevisions to unproven services list and updated reference links

Effective DateApr 1, 2025

Next Review Date

Key ActionVerify prior authorization and medical necessity against the applicable benefit plan and InterQual criteria before scheduling TMJ surgical procedures.

SourceLink

On This Page

Randomized trial evidence demonstrates benefit at 3–6 months when PT is added to splint and education

FDA safety communications (e.g., jaw remodeling devices) should be reviewed when applicable

Billing Rule

Applicable Codes and Coverage

Listing of a code in this policy is for reference only and does not guarantee coverage or payment. Benefit coverage is determined by federal, state, or contractual requirements and applicable laws.

Applicable codes provided in the policy are for reference and may not be all-inclusive
Inclusion of a code does not imply a right to reimbursement

Denial Risk

Denial Risk for Unproven Therapies

Therapies lacking quality evidence are considered not medically necessary and carry a high risk of denial. Providers should document medical necessity and prior conservative management where applicable.

Examples of therapies with insufficient evidence: craniosacral therapy, epigenetic appliances, jaw mobility mechanical stretching devices
Denials likely if these unproven therapies are billed without supporting evidence of benefit

Documentation Required

Benefit Plan Governing Terms

Benefit coverage decisions are governed by the member's federal, state, or contractual benefit plan. In the event of any conflict between this policy and the governing benefit terms, the governing terms prevail. Always check plan-specific terms before rendering services.

Coverage determinations must reference applicable federal, state, or contractual requirements
This policy is informational and may be modified by UnitedHealthcare as necessary

Note

Conservative First‑Line Therapy

Conservative, reversible, evidence‑based therapies are recommended as first-line management for TMD. Surgery should generally be reserved for patients with persistent moderate to severe symptoms after nonsurgical therapy has failed.

First-line: NSAIDs, soft diet, jaw rest, moist heat, physical therapy, splints, muscle relaxants, antidepressants
Surgical intervention indicated only after ineffective nonsurgical therapy and with moderate to severe pain or dysfunction

DefinitionA stabilization (occlusal) or mandibular repositioning device intended to reduce clenching/bruxism and to position the jaw in a more relaxed posture to relieve myofascial pain and TMJ symptoms.

TypesStabilization splints (hard/soft), mandibular repositioning splints (anterior repositioning), prefabricated and custom appliances.

Intended effectsReduce/eliminate tooth grinding, redistribute occlusal forces, decrease muscle tension, and improve pain and mouth opening in TMD patients.

Evidence noteNetwork meta-analyses of RCTs show varying quality of evidence (very low to moderate) supporting splint therapy for arthrogenous and myogenous TMDs; multimodal therapy with counseling + hard stabilization splint may yield maximal improvement.

inv-29: Trigger point injection — key value definition for injections into myofascial trigger points

DefinitionInjection(s) targeted to myofascial trigger points in masticatory muscles to relax muscle fibers, interrupt the pain–tension cycle, and increase range of motion; may be performed as dry needling or with injection of substances (local anesthetic, corticosteroid, dextrose, saline, PRP, or botulinum toxin-A).

IndicationsUsed for myofascial (myogenic) TMD to reduce localized muscle pain and improve maximum mouth opening and pressure pain thresholds.

Evidence noteNetwork meta-analysis of 21 RCTs (959 participants) found short‑term improvements in pain and MMO with various needling therapies, but overall evidence quality was low to very low and no definitive conclusions about superiority of specific substances/types could be made.

inv-30: Jaw mobility devices / Epigenetic appliances — key value definition describing passive stretching devices and epigenetic appliance claims

DefinitionPassive stretching devices for mandibular hypomobility used for prolonged low‑load stretching (examples include TheraBite and Jaw Dynasplint); and intraoral 'epigenetic' appliances that claim overnight pressure can remodel jaws via stimulation of bone cells.

ExamplesTheraBite Jaw Motion Rehabilitation System, Jaw Dynasplint System, OraStretch Press, Therapacer Jaw Mobilizer; epigenetic appliances resemble orthodontic retainers and include devices such as Homeoblock, DNA, and ALF variants.

Coverage stanceListed as unproven and not medically necessary due to insufficient quality evidence to support efficacy for TMD.

inv-31: Arthrogenous TMD — key value definition describing joint-origin TMD and evaluated treatments

DefinitionTemporomandibular disorders originating from the joint (arthrogenous), including internal derangement and joint pathology where pain and limited mouth opening are predominant features.

Evaluated treatmentsTreatments assessed include intra‑articular injections (corticosteroids, hyaluronic acid), arthrocentesis, arthroscopy, and open joint surgery (arthroplasty/arthroplasty with graft or prosthesis).

Evidence summaryNetwork meta-analyses suggest minimally invasive procedures (arthroscopy, intra‑articular injections including corticosteroids or HA) may provide superior short‑ and intermediate‑term pain control and MMO improvement compared with conservative therapy, though evidence quality ranges from very low to moderate.

inv-32: Myofascial (myogenic) TMD — key value definition describing muscle-origin TMD and targeted therapies

DefinitionTMD arising from the masticatory muscles (myofascial/myogenic), characterized by muscle pain, trigger points, and reduced mouth opening; treatments target muscle dysfunction and pain modulation.

Targeted therapiesNeedling therapies (dry or wet needling with LA, BTX‑A, PRP), trigger point injections, physical therapy including TMJ and cervical mobilization, and occlusal splint therapy as part of multimodal care.

Evidence noteRCTs and meta-analyses show some short‑term improvements in pain and MMO with needling and with adding physical therapy to splint therapy, but overall evidence quality is low to moderate and findings are limited by indirectness and heterogeneity.

inv-33: Examples include TheraBite Jaw Motion Rehabilitation System and Jaw Dynasplint System — examples of jaw mobility mechanical stretching devices

ExamplesTheraBite Jaw Motion Rehabilitation System and Jaw Dynasplint System are representative jaw mobility mechanical stretching devices cited in the literature and policy discussions.

Regulatory/coding noteThese devices are specifically named in the policy's revised list of unproven/not medically necessary services and have associated DME coding references (e.g., E1700).

Evidence summaryRandomized trials and feasibility studies (e.g., Zatarain 2018; Lee et al. 2018) show limited or inconsistent evidence, often with low compliance; overall efficacy versus standard exercises is inconclusive.

2025-04-01coverage_rationale_revised

Revised list of unproven and not medically necessary services: replaced prior wording for passive rehabilitation devices with 'jaw mobility mechanical stretching devices' (e.g., TheraBite, Jaw Dynasplint) and expanded examples of epigenetic appliances to add Advanced Lightwire Functional (ALF) appliances; supporting information updated and prior version CS195NE.H archived.